PE20121401A1 - Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st - Google Patents

Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st

Info

Publication number
PE20121401A1
PE20121401A1 PE2012000036A PE2012000036A PE20121401A1 PE 20121401 A1 PE20121401 A1 PE 20121401A1 PE 2012000036 A PE2012000036 A PE 2012000036A PE 2012000036 A PE2012000036 A PE 2012000036A PE 20121401 A1 PE20121401 A1 PE 20121401A1
Authority
PE
Peru
Prior art keywords
treatment
myocardial infarction
elevation
otamixaban
alteration
Prior art date
Application number
PE2012000036A
Other languages
English (en)
Inventor
Jens Stechl
Angele Moryusef
Christophe Gaudin
Pascale Ythier-Moury
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20121401A1 publication Critical patent/PE20121401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDO AL COMPUESTO ESTER METILICO DEL ACIDO (2R,3R)-2-(3-CARBAMIMIDOIL-BENCIL)-3-[4-(1-OXI-PIRIDIN-4-IL)BENZOILAMINO]-BUTIRICO, QUE ES ADMINISTRADO EN UNA CANTIDAD ENTRE 0.070MG/KG DE PESO CORPORAL/H Y 0.105MG/KG DE PESO CORPORAL/H. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE INFARTO DE MIOCARDIO SIN ELEVACION DEL SEGMENTO ST
PE2012000036A 2009-07-29 2010-07-22 Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st PE20121401A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290601 2009-07-29
EP10305192 2010-02-26

Publications (1)

Publication Number Publication Date
PE20121401A1 true PE20121401A1 (es) 2012-10-25

Family

ID=42542846

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000036A PE20121401A1 (es) 2009-07-29 2010-07-22 Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st

Country Status (25)

Country Link
US (1) US9492437B2 (es)
EP (1) EP2459193A1 (es)
JP (1) JP2013500298A (es)
KR (1) KR20120038982A (es)
CN (1) CN102470128A (es)
AR (1) AR077427A1 (es)
AU (1) AU2010277725B2 (es)
BR (1) BR112012001900A2 (es)
CA (1) CA2766533A1 (es)
CL (1) CL2012000196A1 (es)
CO (1) CO6491041A2 (es)
CR (1) CR20110674A (es)
DO (1) DOP2012000012A (es)
EC (1) ECSP12011627A (es)
IL (1) IL217612A (es)
MA (1) MA33455B1 (es)
MX (1) MX2012000457A (es)
NI (1) NI201200008A (es)
NZ (1) NZ597957A (es)
PE (1) PE20121401A1 (es)
RU (1) RU2542455C2 (es)
SG (1) SG177772A1 (es)
TW (1) TWI463982B (es)
UY (1) UY32807A (es)
WO (1) WO2011012527A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012234323A1 (en) 2011-03-29 2013-10-17 Sanofi Otamixaban formulations with improved stability
SI2691371T1 (sl) * 2011-03-29 2015-07-31 Sanofi Sol benzojske kisline otamiksabana
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
EA201590473A1 (ru) * 2012-08-31 2015-06-30 Санофи Отамиксабан для применения в лечении острого коронарного синдрома без подъема st у пациентов, которым планируется проведение аортокоронарного шунтирования

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO117913B1 (ro) * 1996-01-02 2002-09-30 Aventis Pharmaceuticals Inc. Derivaţi de n-[(amino-(imino)metil)fenil]propil amide substituite, compoziţie farmaceutică care îi conţine şi metodă de tratament
RU2225617C1 (ru) * 2002-12-16 2004-03-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st

Also Published As

Publication number Publication date
RU2542455C2 (ru) 2015-02-20
CA2766533A1 (en) 2011-02-03
BR112012001900A2 (pt) 2016-03-15
RU2012107483A (ru) 2013-09-10
US9492437B2 (en) 2016-11-15
ECSP12011627A (es) 2012-02-29
CR20110674A (es) 2012-04-17
CN102470128A (zh) 2012-05-23
CL2012000196A1 (es) 2012-10-05
US20120238605A1 (en) 2012-09-20
TWI463982B (zh) 2014-12-11
EP2459193A1 (en) 2012-06-06
WO2011012527A1 (en) 2011-02-03
KR20120038982A (ko) 2012-04-24
UY32807A (es) 2011-02-28
SG177772A1 (en) 2012-03-29
NZ597957A (en) 2014-05-30
AR077427A1 (es) 2011-08-24
JP2013500298A (ja) 2013-01-07
MX2012000457A (es) 2012-01-27
NI201200008A (es) 2012-05-29
AU2010277725B2 (en) 2016-08-18
TW201119655A (en) 2011-06-16
IL217612A (en) 2014-08-31
DOP2012000012A (es) 2012-02-15
CO6491041A2 (es) 2012-07-31
MA33455B1 (fr) 2012-07-03
AU2010277725A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
PE20120797A1 (es) Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
PE20140099A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
GT201300308A (es) Combinación de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
CL2011002989A1 (es) Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros.
BR112014000876A2 (pt) composições em gel de oximetazolina e métodos de uso
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
PE20110297A1 (es) Inhibidores de dpp-4 para la cicatrizacion de heridas
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
GT200900328A (es) Derivados de bencimidazol
PE20081736A1 (es) Compuestos triciclicos, composiciones, y procedimientos
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
GB2511685A (en) Muscarinic m1 receptor agonists
IN2014DN08886A (es)
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
PE20142318A1 (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR

Legal Events

Date Code Title Description
FA Abandonment or withdrawal